Author information from the last article
Avdeling for immunologi og transfusjonsmedisin
Oslo universitetssykehus
Forfatterbidrag: analyse og tolking av data, litteratursøk, utarbeiding og godkjenning av manuskriptet.
Fridtjof Lund-Johansen er dr.med. og forsker.
Articles by Fridtjof Lund-Johansen
Convalescent plasma from Norwegian blood donors to treat COVID-19
- Lise Sofie Haug Nissen-Meyer,
- Tine Torsvik Steinsvåg,
- Mona Høysæter Fenstad,
- Ingvild Hausberg Sørvoll,
- Marte Hvalryg,
- Thomas Larsen Titze,
- Karin Magnussen,
- Gunn Kristoffersen,
- Kathrine Margrethe Neuman Johnsen,
- Abid Hussain Llohn,
- Brita Hermundstad,
- Lilja Synnøve Høiback,
- Morten Haugen,
- Einar K. Kristoffersen,
- Line Boulland,
- Anne-Marte Bakken Kran,
- Fridtjof Lund-Johansen,
- John Torgils Vaage,
- Øystein Flesland,
- Tor Audun Hervig
03.08.2023:
Convalescent plasma for the treatment of COVID-19 is a blood component from a donor who has recovered from COVID-19. Despite uncertainty about its efficacy, many countries, including Norway, initiated the collection and use of COVID-19 convalescent plasma. The set-up and background of the Norwegian...
COVID-19 patients treated with convalescent plasma
- Lise Sofie Haug Nissen-Meyer,
- Magnhild Eide Macpherson,
- Linda Gail Skeie,
- Marte Hvalryg,
- Abid Hussain Llohn,
- Tine Torsvik Steinsvåg,
- Mona Høysæter Fenstad,
- Anders Tveita,
- Einar K. Kristoffersen,
- Tatjana Sundic,
- Fridtjof Lund-Johansen,
- John Torgils Vaage,
- Øystein Flesland,
- Anne Ma Dyrhol-Riise,
- Jan Cato Holter,
- Tor Audun Hervig,
- Børre Fevang
03.08.2023:
COVID-19 convalescent plasma (NORPLASMA) (1) first became available to Norwegian patients in the spring of 2020. The Norwegian Directorate of Health recommended use of the product in patients who were at risk of developing a severe/life-threatening course of COVID-19, where the attending doctor...